𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors

✍ Scribed by Jolanta Polanowska; Laurent Le Cam; Béatrice Orsetti; Heléne Vallés; Eric Fabbrizio; Lluis Fajas; Sylvie Taviaux; Charles Theillet; Claude Sardet

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
113 KB
Volume
28
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis

E2F transcription factors (E2F1 to 6) are central players in the control of animal cell proliferation as regulators of genes involved in cell cycle progression and in transformation. In this report, we have investigated the potential involvement of the E2F5 gene in tumorigenesis. We show that E2F5 can promote the formation of morphologically transformed foci in primary baby rat kidney cells (BRK) when it is overexpressed in the presence of its heterodimeric partner DP1 and activated RAS. This suggests that E2F5 behaves like a MYC-type cooperating oncogene in functional assays, prompting us to monitor potential amplifications of the E2F5 gene in primary human tumors. We mapped the human E2F5 gene to 8q21.1-21.3 equidistant from the MOS (8q12) and MYC (8q24) oncogenes. Since the long arm of chromosome 8 is frequently the site of increased gene copy number (ICN) in breast cancer, we screened 442 breast tumor DNAs for gains of E2F5, MOS, and MYC genes. The three genes showed ICN, albeit at variable incidence and levels of amplification, with the ICN of E2F5 occurring concomitantly with those of MOS and/or MYC in almost half of the cases. Moreover, a marked increase of the 2.5-kb E2F5 transcript was also detected in some tumors and tumor cell lines. In conclusion, the evidence that sustained unregulated expression of E2F5 can cooperate with other oncogenes to promote cell transformation in functional assays, together with the detection of chromosomal amplifications and overexpressions of the E2F5 gene in breast tumors, provides the first indications that E2F5 deregulation may have a role in human tumor development.

📜 SIMILAR VOLUMES

MYCN Is the only highly expressed gene f
MYCN Is the only highly expressed gene from the core amplified domain in human neuroblastomas
✍ Jill L. Reiter; Garrett M. Brodeur 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

MYCN amplification in neuroblastomas is strongly associated with advanced stages of disease and a poor prognosis. We have recently defined a 130 kb core region of the MYCN amplicon that is consistently amplified in neuroblastomas. However, it has been argued that other expressed sequences were coamp

Isolation and characterization of a nove
Isolation and characterization of a novel human pancreas-specific gene, pancpin, that is down-regulated in pancreatic cancer cells
✍ Kouichi Ozaki; Masami Nagata; Mikio Suzuki; Tsutomu Fujiwara; Yasuo Miyoshi; Osa 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 254 KB 👁 1 views

By means of the differential display method, we isolated a novel human gene that is expressed specifically in pancreas. The cDNA, designated ''pancpin,'' contained an open reading frame of 1,215 nucleotides encoding a 405 amino acid protein, showing a high degree of similarity to serine protease inh

The potent anti-proliferative effect of
The potent anti-proliferative effect of 20-EPI analogues of 1,25 dihydroxyvitamin D3 in human breast-cancer MCF-7 cells is related to promoter selectivity
✍ Christina Mørk Hansen; Carina Danielsson; Carsten Carlberg 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 458 KB 👁 1 views

The hormone I ,25-dihydroxyvitamin D3 (VD) has a potential use as an anti-tumor agent, but its clinical applications are restricted by its strong calcemic activity. This has led to the development of VD analogues with selectively increased growthinhibitory activity. One of the most potent analogues